Scott Caroen - Concepedia

Author

Scott Caroen

Walter Reed National Military Medical Center ORCID

Also Known As

S. Caroen, S., Caroen, Scott Caroen, Scott Z. Caroen

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Walter Reed National Military Medical Center University of California San Diego Moores Cancer Center Epicentre (South Africa)La Jolla Bioengineering Institute

About

Scott Caroen is an author at Walter Reed National Military Medical Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	14	267
2	Cell Biology	2	2	88
3	Health Sciences	1	1	11
4	Natural Sciences	1	1	39
5	Biomolecular Engineering	1	1	11

Scott Caroen

Publications

459

Citations

H-Index

Page 1

	Year	Citations
REPLATINUM Phase III Randomized Study: RRx-001 + Platinum Doublet Versus Platinum Doublet in Third-Line Small Cell Lung Cancer Bryan Oronsky, Tony R. Reid, Christopher Larson, Future Oncology Platinum DoubletMedicineMetronomic TherapyPhase Iii TrialObjective Response Rate	2019	49
Nucleocapsid as a next-generation COVID-19 vaccine candidate Bryan Oronsky, Christopher Larson, Scott Caroen, International Journal of Infectious Diseases VaccinationSpike ProteinVaccine DevelopmentVaccine TargetVaccine Surveillance	2022	41
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development Bryan Oronsky, Xiaoning Guo, Xiaohui Wang, Journal of Medicinal Chemistry Tumor Targeted CytotoxicityImmunologyPathologyPharmacotherapyCancer Biology	2021	39
Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial Michelle M. Kim, Hemant Parmar, Yue Cao, Translational Oncology	2016	31
Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells Bryan Oronsky, Tony R. Reid, Arnold L. Oronsky, Oncotarget	2018	22
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic" Bryan Oronsky, Corey A. Carter, Scott Caroen, OncoImmunology	2020	21
The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent Jan Scicinski, George A. Fisher, Corey Carter, Redox Biology	2015	17
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001 Corey A. Carter, Bruno A. Schmitz, Paul Peterson, Case Reports in Oncology Tumor FlareEndocrine OncologyOncologyMedicineImmunology	2016	17
Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization Corey A. Carter, Bryan Oronsky, Scott Caroen, Case Reports in Oncology	2016	16
PREVLAR: Phase 2a Randomized Trial to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Head and Neck Chemoradiotherapy Marcelo Bonomi, Dukagjin Blakaj, Rafi Kabarriti, International Journal of Radiation OncologyBiologyPhysics	2023	16

Page 1